Browsing Tag
Phase 3 trials
6 posts
CD388 in focus as Merck announces $9.2bn deal for Cidara Therapeutics (NASDAQ: CDTX)
Merck is acquiring Cidara Therapeutics for $9.2B to expand into long-acting antivirals. Find out what makes CD388 a potential flu game-changer.
Is Ocular Therapeutix the next big biotech buyout? Takeover rumors spark investor frenzy
Ocular Therapeutix stock jumps on takeover rumors. Find out what analysts are saying, and why Axpaxl could make it biotech’s next big M&A target.
Theravance completes enrollment in Phase 3 CYPRESS trial for ampreloxetine in MSA-related nOH
Theravance completes Phase 3 enrollment for ampreloxetine in MSA-related nOH. Topline data expected in Q1 2026. Could this be a rare disease breakthrough?
Moleculin Biotech (NASDAQ: MBRX) launches stock offering to support pivotal cancer drug trial and IND filings
Moleculin Biotech to raise $5.9M to fund its Phase 3 trial for Annamycin and expand oncology pipeline. Explore what this means for AML treatment and investors.
UAE grants emergency use authorization for Sputnik V Covid-19 vaccine
The Russian Direct Investment Fund (RDIF) has announced that the UAE Ministry of Health and Prevention (MOHAP) has…
Mirum Pharmaceuticals raises $120m to advance Maralixibat for rare liver diseases
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to…